MWNA
KYNB

Marshall Wace North America’s Kyntra Bio KYNB Stock Holding History

Marshall Wace North America’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-38,000
Closed -$33.8M – 1288
2019
Q1 		$33.8M Buy
+38,000
New +$51.5M 0.24% 102

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Marshall Wace North America's KYNB Position: Q4 2020 in Review

Marshall Wace North America sold out of Kyntra Bio (KYNB) in Q4 2020, closing a stake of 1,268 shares — an estimated $1.3M sold.

Marshall Wace North America first reported a position in KYNB in Q3 2017 and held it in 6 quarters. The position peaked at $3.59M in Q3 2017. 207 funds tracked by Wall St. Rank hold KYNB as of Q4 2020.

  • Marshall Wace North America reported no remaining Kyntra Bio position as of Q4 2020 after selling out during the quarter.
  • Marshall Wace North America sold 1,268 Kyntra Bio shares in Q4 2020, an estimated $1.3M.
  • Marshall Wace North America first reported a position in Kyntra Bio in Q3 2017 and held it in 6 quarters.
  • Marshall Wace North America's Kyntra Bio position peaked at $3.59M in Q3 2017.
  • 207 funds tracked by Wall St. Rank held Kyntra Bio as of Q4 2020.

Based on Marshall Wace North America's 13F filing for Q4 2020, filed 16 Feb 2021.